Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07122193 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Study acronym: PLATINUM US
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 2026 to Jun 5, 2026
    • Study completion moved earlier from Jan 2028 to Sep 2027
    v24
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 28 of 28 sites
    v23
  3. Eligibility criteria expanded, about 6 words
    • Primary endpoint revised
    v22
  4. Study sites: 27 to 28v21
  5. Study sites: 26 to 27v20
Show 18 earlier versionsHide 18 earlier versions
  1. Study sites: 25 to 26v19
  2. Study sites: 22 to 25v18
  3. Study sites: 20 to 22v17
  4. Study sites: 19 to 20v16
  5. Study sites: 18 to 19v15
  6. Study sites: 17 to 18v14
  7. Study sites: 15 to 17v13
  8. Study sites: 14 to 15v12
  9. Study sites: 12 to 14v11
  10. Study sites: 11 to 12v10
  11. Study sites: 10 to 11v9
  12. Study sites: 9 to 10v8
  13. Study sites: 7 to 9v7
  14. Study sites: 6 to 7v6
  15. Study sites: 5 to 6v5
  16. Study sites: 4 to 5v4
  17. Study sites: 1 to 4v3
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2025 to Aug 27, 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
Trial Details
NCT Number NCT07122193
Lead Sponsor Merz North America, Inc.
Conditions
(from sponsor)		 Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents +2 more
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov